FOLD
ANALYST COVERAGE24 analysts
BUY
+0.1%upside to target
Buy
1667%
Hold
729%
Sell
14%
16 Buy (67%)7 Hold (29%)1 Sell (4%)
Full report →
PRICE
Prev Close
14.49
Open
14.49
Day Range
52W Range5.51 – 14.50
5.51
14.50
100% of range
VOLUME & SIZE
Avg Volume
4.2M
FUNDAMENTALS
P/E Ratio
-161.0x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.19
Market-like
TECHNICAL
RSI (14)
72
Overbought
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 115 days
Sep 10
Key MetricsTTM
Market Cap$4.55B
Revenue TTM$634.21M
Net Income TTM-$27.11M
Free Cash Flow$29.85M
Gross Margin87.9%
Operating Margin5.2%
Net Margin-4.3%
Return on Equity-12.0%
Return on Assets-2.9%
Debt / Equity1.76
Current Ratio2.84
EPS TTM$-0.09

FOLD News

About

amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
John Crowley
Jill WeimerChief Science Officer
David ClarkChief People Officer
Simon Nicolas Reade HarfordChief Financial Officer
Jeffrey CastelliChief Development Officer
Andrew FaughnanVice President of Investor Relations
Bradley L. CampbellChief Executive Officer, President & Director
Brendan McEvoyExecutive Director of External Communications
Patrik S. FlorencioGlobal Chief Compliance & Risk Officer
Ellen S. RosenbergChief Legal Officer & Corporate Secretary
Samantha ProutChief Accounting Officer & Controller